Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual MeetingBusiness Wire • 05/21/24
Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule ManagementBusiness Wire • 05/08/24
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual MeetingBusiness Wire • 04/09/24
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private PlacementBusiness Wire • 04/05/24
Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer CenterBusiness Wire • 03/25/24
Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business HighlightsBusiness Wire • 03/01/24
Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024Business Wire • 02/16/24
Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw MethodBusiness Wire • 11/14/23